-
公开(公告)号:US4259328A
公开(公告)日:1981-03-31
申请号:US914778
申请日:1978-06-12
申请人: Geza Szilagyi , Endre Kasztreiner , Judit Kosary , Peter Matyus , Zsuzsa Huszti , Gyorgy Cseh , Agnes Kenessey , Laszlo Tardos , Edit Kosa , Laszlo Jaszlits , Sandor Elek , Istvan Elekes , Istvan Polgari
发明人: Geza Szilagyi , Endre Kasztreiner , Judit Kosary , Peter Matyus , Zsuzsa Huszti , Gyorgy Cseh , Agnes Kenessey , Laszlo Tardos , Edit Kosa , Laszlo Jaszlits , Sandor Elek , Istvan Elekes , Istvan Polgari
IPC分类号: A61K31/50 , A61P9/12 , C07D237/20 , C07D237/22 , C07D237/24 , C07D401/04 , C07D295/00 , A61K31/535
CPC分类号: C07D237/24 , C07D237/20 , C07D237/22
摘要: Pyridazinylhydrazones capable of lowering blood pressure having the formula ##STR1## wherein R.sup.1 is hydrogen, chlorine, alkyl having from 1 to 4 carbon atoms, methoxy, hydroxyl, carbamoyl or cyano;R.sup.2 is morpholino; andK is a group having the formula ##STR2## wherein one of R.sup.3, R.sup.4, R.sup.5 or R.sup.6 is carboxyl or alkoxycarbonyl.
摘要翻译: 能够降低血压的哒嗪基腙类具有下式:其中R1是氢,氯,具有1-4个碳原子的烷基,甲氧基,羟基,氨基甲酰基或氰基; R2是吗啉代; 并且K是具有式“IMAGE”的基团,其中R 3,R 4,R 5或R 6中的一个是羧基或烷氧基羰基。
-
公开(公告)号:US4308386A
公开(公告)日:1981-12-29
申请号:US89859
申请日:1979-10-31
申请人: Szilagyi Geza , Endre Kasztreiner , Judit Kosary , Peter Matyus , Zsuzsa Huszti , Gyorgy Cseh , Agnes Kenessey , Laszlo Tardos , Edit Kosa , Laszlo Jaszlits , Sandor Elek , Istvan Elekes , Istvan Polgari
发明人: Szilagyi Geza , Endre Kasztreiner , Judit Kosary , Peter Matyus , Zsuzsa Huszti , Gyorgy Cseh , Agnes Kenessey , Laszlo Tardos , Edit Kosa , Laszlo Jaszlits , Sandor Elek , Istvan Elekes , Istvan Polgari
IPC分类号: A61K31/50 , A61P9/12 , C07D237/20 , C07D237/22 , C07D237/24 , C07D401/04
CPC分类号: C07D237/24 , C07D237/20 , C07D237/22
摘要: Pyridazinylhydrazones capable of lowering blood pressure have the formula ##STR1## wherein R.sup.1 is hydrogen, chlorine, alkyl having from 1 to 4 carbon atoms, methoxy, hydroxyl, carbamoyl or cyano;R.sup.2 is chloro; andK is a group having the formula ##STR2## wherein one of R.sup.3, R.sup.4, R.sup.5 or R.sup.6 is carboxyl or alkoxycarbonyl.
摘要翻译: 能够降低血压的哒嗪基腙具有式“IMAGE”,其中R 1是氢,氯,具有1至4个碳原子的烷基,甲氧基,羟基,氨基甲酰基或氰基; R2是氯; 并且K是具有式“IMAGE”的基团,其中R 3,R 4,R 5或R 6中的一个是羧基或烷氧基羰基。
-
公开(公告)号:US4244871A
公开(公告)日:1981-01-13
申请号:US58363
申请日:1979-07-12
申请人: Judit Kosary , Endre Kasztreiner , Zsuzsa Huszti , Agnes Kenessey , Gyorgy Cseh , Veronika Szilagyi nee Pap , Judit Stverteczky nee Sztrokay
发明人: Judit Kosary , Endre Kasztreiner , Zsuzsa Huszti , Agnes Kenessey , Gyorgy Cseh , Veronika Szilagyi nee Pap , Judit Stverteczky nee Sztrokay
IPC分类号: A61K31/63 , A61P9/12 , C07C20060101 , C07C67/00 , C07C301/00 , C07C311/39 , C07D295/08 , C07D295/14 , C07D295/155 , C07D295/16 , C07D295/18 , C07D295/192 , C07D413/10 , C07C103/22 , C07C143/80 , C07D265/28
CPC分类号: C07D295/192 , A61K31/63 , C07D295/14 , C07D295/155 , C07D295/18 , C07D413/10 , C07C2101/14
摘要: The invention relates to novel sulfonamidobenzoic acid derivatives having the general formula ##STR1## wherein R.sup.1 denotes a C.sub.1-4 alkoxy group or a hydrazino group or an NR.sup.4 R.sup.5 group, wherein R.sup.4 and R.sup.5 denote each a hydrogen atom or an identical or different C.sub.1-4 alkyl group; furthermore R.sup.4 may denote an aralkyl or substituted aralkyl group provided that R.sup.5 denotes a hydrogen atom; furthermore NR.sup.4 R.sup.5 may denote a morpholine or piperazine ring;R.sup.2 and R.sup.3 may denote each a hydrogen atom or an identical or different C.sub.1-4 aliphatic group; furthermore R.sup.2 may denote a cycloaliphatic, aralkyl, substituted aralkyl or amino group provided that R.sup.3 denotes a hydrogen atom; furthermore R.sup.2 and R.sup.3 may denote together with the adjacent nitrogen atom a morpholino ring, an unsubstituted piperazine ring or a substituted piperazine ring,and to their pharmaceutically acceptable acid addition salts. Furthermore, the invention relates to a process for preparing these compounds.The novel sulfonamidobenzoic acid derivatives having the general formula I possess significant tyrosine-paralyzing activity and thus they retard the biosynthesis of noradrenaline.
摘要翻译: 本发明涉及具有通式
的新型磺酰胺基苯甲酸衍生物,其中R 1表示C 1-4烷氧基或肼基或NR 4 R 5基,其中R 4和R 5各自表示氢原子或相同或不同的C 1-4 烷基; 此外,R 4可以表示芳烷基或取代的芳烷基,条件是R 5表示氢原子; 此外NR4R5可以表示吗啉或哌嗪环; R2和R3可以表示氢原子或相同或不同的C1-4脂族基团; 此外,R 2可以表示脂环族,芳烷基,取代的芳烷基或氨基,条件是R 3表示氢原子; 此外R2和R3可以与相邻的氮原子一起表示吗啉代环,未取代的哌嗪环或取代的哌嗪环,以及它们的药学上可接受的酸加成盐。 此外,本发明涉及一种制备这些化合物的方法。 具有通式I的新型磺酰胺基苯甲酸衍生物具有显着的酪氨酸 - 麻痹活性,因此它们延缓了去甲肾上腺素的生物合成。 -
公开(公告)号:US4826845A
公开(公告)日:1989-05-02
申请号:US924445
申请日:1986-10-29
申请人: Endre Kasztreiner , Gyorgy Rablocsky , Nandor Makk , Laszlo Jaszlits , Peter Matyus , Gyorgy Cseh , Ildiko Pribusz nee Rapp , Klara Czako , Eszter Diesler , Istvan Elekes , Laszlo Kaufer , Maria Kuhar nee Kurthy , Judit Kincsessy , Judit Kosary , Gyongyi Nagy nee Csokas
发明人: Endre Kasztreiner , Gyorgy Rablocsky , Nandor Makk , Laszlo Jaszlits , Peter Matyus , Gyorgy Cseh , Ildiko Pribusz nee Rapp , Klara Czako , Eszter Diesler , Istvan Elekes , Laszlo Kaufer , Maria Kuhar nee Kurthy , Judit Kincsessy , Judit Kosary , Gyongyi Nagy nee Csokas
IPC分类号: C07D237/00 , A61K31/50 , A61K31/535 , A61P9/12 , C07D237/08 , C07D237/12 , C07D237/14 , C07D237/20 , C07D237/22 , C07D319/00 , C07D403/04 , C07D405/12 , C07D521/00 , C07D405/06
CPC分类号: C07D231/12 , C07D233/56 , C07D237/08 , C07D237/12 , C07D237/20 , C07D249/08 , C07D403/04 , C07D405/12
摘要: The invention relates to novel 3(2H)-pyridazinone-derivatives of the general formula (I), pharmaceutical compositions containing them and process for their preparation. In the general formula (I) ##STR1## stands for an ethyl or propyl group substituted by a terminal halogen atom or a hydroxyl or NR.sup.1 R.sup.2 group, whereinR.sup.1 represents hydrogen atom or an unsubstituted or optionally substituted benzyl group;R.sup.2 represents hydrogen atom or an unsubstituted or optionally substituted benzo[1,4]dioxan-2-yl-methyl or -ethyl group or a (CH.sub.2).sub.n --R.sup.3 group, whereinn is 2 or 3; andR.sup.3 stands for an unsubstituted or optionally substituted phenoxy or phenylthio group; andX stands for a hydrogen or halogen atom or an unsubstituted or optionally substituted, saturated or unsaturated 5- or 6-membered heterocyclic group containing a nitrogen atom and optionally an additional heteroatom, e.g. an oxygen, sulfur or nitrogen atom,with the proviso that R is different from an ethyl or propyl group substituted terminally by a hydroxyl group or halogen atom when X represents a hydrogen or chlorine atom.The compounds of general formula (I) selectively inhibit the adrenergic alpha.sub.1 receptors, have a calcium-antagonistic effect and exert blood pressure lowering action.
摘要翻译: 本发明涉及通式(I)的新的3(2H) - 哒嗪酮衍生物,含有它们的药物组合物及其制备方法。 在通式(I)中,(I)表示被末端卤素原子或羟基或NR 1 R 2基团取代的乙基或丙基,其中R 1表示氢原子或未取代或任意取代的苄基; R 2表示氢原子或未取代或任选取代的苯并[1,4]二氧杂环己烷-2-基 - 甲基或 - 乙基或(CH 2)n -R 3基团,其中n为2或3; R3代表未取代或任选取代的苯氧基或苯硫基; X代表氢或卤素原子,或未取代或任选取代的饱和或不饱和的含有氮原子和任选另外的杂原子的5或6元杂环基团。 氧,硫或氮原子,条件是当X表示氢或氯原子时,R不同于被羟基或卤素原子末端取代的乙基或丙基。 通式(I)的化合物选择性地抑制肾上腺素α1受体,具有钙拮抗作用并发挥降血压作用。
-
公开(公告)号:US4287194A
公开(公告)日:1981-09-01
申请号:US55263
申请日:1979-07-06
申请人: Edit Kosa , Janos Borvendeg , Zsuzsanna Huszti , Judit Kosary , Geza Szilagyi , Laszlo Tardos , Endre Kasztreiner , Laszlo Nagy , Erzsebet Szuucs , Gabriella Kiss
发明人: Edit Kosa , Janos Borvendeg , Zsuzsanna Huszti , Judit Kosary , Geza Szilagyi , Laszlo Tardos , Endre Kasztreiner , Laszlo Nagy , Erzsebet Szuucs , Gabriella Kiss
IPC分类号: A61K31/13 , A61K31/135 , A61K31/165 , A61K31/40 , A61K31/50 , A61K31/535 , A61P9/12 , A61K31/235 , A61K31/495
摘要: A pharmaceutical compositions with hypotensive effects which comprise a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof, ##STR1## wherein R.sup.1 is formula (II) ##STR2## wherein R.sup.4 and R.sup.5 each represent hydrogen, hydroxy, nitro at the same timeR.sup.2 and R.sup.3 are hydrogen, orR.sup.1 are 3-chloro-6-pyridazinylamino, 3-methyl-6-pyridazinylamino or 3-carbamoyl-6-pyridazinylamino, and at the same timeR.sup.2 and R.sup.3 form together formula (III), ##STR3## wherein R.sup.6 is C.sub.1-4 alkyl group,R.sup.7 is hydrogen or a C.sub.1-4 alkyl group, andn is an integer of 1 to 3, orR.sup.2 and R.sup.3 form together a group of the general formula (IV),=Q-R.sup.8 (IV)whereinQ is C.sub.5-7 cycloaliphatic, andR.sup.8 is hydrogen, a C.sub.1-4 alkoxycarbonyl or a C.sub.2-4 alkyl,and a compound of formula (V) or a pharmaceutically acceptable acid addition salt thereof, ##STR4## wherein R.sup.9 is naphthyl, 4-indolyl or 4-morpholino-1,2,5-thiadiazol-3-yl group or ##STR5## .
摘要翻译: 具有降血压作用的药物组合物,其包含式(I)化合物或其药学上可接受的酸加成盐,其中R 1为式(II)其中R 4和R 5各自表示氢 ,羟基,硝基,同时R2和R3是氢,或R1是3-氯-6-哒嗪基氨基,3-甲基-6-哒嗪基氨基或3-氨基甲酰基-6-哒嗪基氨基,同时R2和R3形成 (III),其中R6为C1-4烷基,R7为氢或C1-4烷基,n为1〜3的整数,或R2和R3一起形成基团 通式(IV)的化合物= Q-R8(Ⅳ)其中Q为C5-7环脂族基,R8为氢,C1-4烷氧基羰基或C2-4烷基,式(Ⅴ)化合物或式 (V)其中R 9为萘基,4-吲哚基或4-吗啉代-1,2,5-噻二唑-3-基或Ⅵ(VI)。
-
-
-
-